Akari's AKTX-101 Demonstrates Superior Preclinical Potency in Cancer, Eyes Phase 1 Study
AKTX has more than doubled off its 52-week low of $3.25.
Summary
Akari Therapeutics announced positive preclinical data for its lead TROP2-targeting antibody-drug conjugate (ADC), AKTX-101, at the AACR Annual Meeting. The data demonstrated superior potency and differentiated cytotoxicity compared to leading TROP2 ADCs across bladder, lung, and breast tumor models, with the potential to overcome resistance to current Topoisomerase I inhibitor ADCs. This news follows the company's recent strategic partnership with WuXi XDC to advance its ADC development, indicating significant progress in its pipeline. For a micro-cap biotech, these strong preclinical results are a critical de-risking event, validating its novel RNA splicing modulator payload and positioning AKTX-101 as a potentially differentiated asset in a rapidly growing market. The company plans to submit an Investigational New Drug (IND) application in Q4 2026 and initiate a Phase 1 study in Q1 2027, which will be key upcoming catalysts.
At the time of this announcement, AKTX was trading at $8.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6M. The 52-week trading range was $3.25 to $63.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.